Gustavo A. Rosario Benitez

Array ( [id] => 15753721 [patent_doc_number] => 10618956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Engineered T cell receptors and immune therapy using the same [patent_app_type] => utility [patent_app_number] => 16/180980 [patent_app_country] => US [patent_app_date] => 2018-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 12 [patent_no_of_words] => 12473 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16180980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414527 [patent_doc_number] => 10822403 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Composition and method for the diagnosis and treatment of iron-related disorders [patent_app_type] => utility [patent_app_number] => 16/179515 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 54849 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16498885 [patent_doc_number] => 10864252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Anti-SSX-2 T cell receptors and related materials and methods of use [patent_app_type] => utility [patent_app_number] => 16/173701 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 25 [patent_no_of_words] => 15266 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16173701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901861 [patent_doc_number] => 20190040135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3 [patent_app_type] => utility [patent_app_number] => 16/168559 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16168559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997871 [patent_doc_number] => 11498965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same [patent_app_type] => utility [patent_app_number] => 16/754431 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7934 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044952 [patent_doc_number] => 11098120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Immunomodulation by anti-CD3 immunotoxins to treat cancers bearing or not uniformly bearing surface CD3 [patent_app_type] => utility [patent_app_number] => 16/153047 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6277 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712897 [patent_doc_number] => 20190247512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => BIFUNCTIONAL POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/151144 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16151144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541020 [patent_doc_number] => 11306131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage [patent_app_type] => utility [patent_app_number] => 16/144226 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 26 [patent_no_of_words] => 15973 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185369 [patent_doc_number] => 20190112389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/144452 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 222937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251178 [patent_doc_number] => 11186650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Anti-CD3 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/144686 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 170 [patent_figures_cnt] => 172 [patent_no_of_words] => 222449 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18133940 [patent_doc_number] => 11559589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy [patent_app_type] => utility [patent_app_number] => 16/137337 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 23 [patent_no_of_words] => 6884 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406903 [patent_doc_number] => 20190169295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => LONG LIFE POLYPEPTIDE BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/126617 [patent_app_country] => US [patent_app_date] => 2018-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16126617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17554954 [patent_doc_number] => 11311611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Antigen-specific T cell receptors and T cell epitopes [patent_app_type] => utility [patent_app_number] => 16/121414 [patent_app_country] => US [patent_app_date] => 2018-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 36780 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 402 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16121414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016593 [patent_doc_number] => 20190070290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => COMPOSITIONS COMPRISING CROSS-SPECIES-SPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/116293 [patent_app_country] => US [patent_app_date] => 2018-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16116293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227259 [patent_doc_number] => 20190125802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant [patent_app_type] => utility [patent_app_number] => 16/103332 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13841131 [patent_doc_number] => 20190024050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION [patent_app_type] => utility [patent_app_number] => 16/100113 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13841131 [patent_doc_number] => 20190024050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION [patent_app_type] => utility [patent_app_number] => 16/100113 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901887 [patent_doc_number] => 20190040148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/047197 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16047197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826679 [patent_doc_number] => 20190016824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/043765 [patent_app_country] => US [patent_app_date] => 2018-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16043765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14214035 [patent_doc_number] => 20190119402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => Compositions for Inhibiting MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/034896 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034896 [rel_patent_id] =>[rel_patent_doc_number] =>)